Effectiveness and safety of toripalimab, camrelizumab and sintilimab in
a real-world cohort of hepatitis B virus associated hepatocellular
carcinoma patients
Abstract
Aims: The investigation regarding the clinical significance of
programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese
patients is rare. This study evaluated safety and efficacy of PD-1 with
Toripalimab, Camrelizumab or Sintilimab for Chinese Hepatocellular
carcinoma (HCC) patients in a real-life cohort. Methods: We
retrospectively analyzed HBV associated HCC patients treated with
Toripalimab, Camrelizumab or Sintilimab in a retrospective cohort from
Nov 2018 to Dec 2019. Efficacy was evaluated with objective response
rate (ORR), disease control rate (DCR), progression-free survival (PFS),
time to tumor progression (TTP) and overall survival (OS). Results:
Seventy eight patients were finally included in the analysis: 26 for
Toripalimab, 36 for Camrelizumab, and 16 for Sintilimab. Mean duration
of follow-up was 22.7 ± 12.6 weeks and the mean Cycles of PD-1 at
cut-off were 4.8 ± 2.7 for all patients. The ORR and DCR for the whole
cohort were 17.9% and 73.1%, respectively. Overall, 21 (26.9%)
patients had radiological disease progression and 6 (7.7%) patients
died during follow-up. Median PFS was 40.7 (95% CI, 34.7-46.7) weeks,
median TTP was 45.7 (95% CI, 40.5-60.0) weeks, and median OS was 51.1
(95% CI, 46.4-55.9) weeks. Most frequent drug-related AEs were Rash
(19.2%), Hypertension (15.4%), Fatigue (12.8%), Paraesthesia
(12.8%), and Diarrhoea (10.3%). Conclusions: Our findings suggest
that: 1. PD-1-targeted immunotherapy with Toripalimab, Camrelizumab or
Sintilimab yielded a promising outcome in Chinese HBV patients with HCC;
2. Immunotherapy was well tolerated generally and had manageable side
effects, which is worth of popularization and application in clinical
practice.